Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET
Company Participants
Jennifer Good – President and Chief Executive Officer
Lisa Delfini – Chief Financial Officer
Bill Forbes – Chief Development Officer
Conference Call Participants
Serge Belanger – Needham & Company
Annabel Samimy – Stifel
Nathan Weinstein – Aegis Capital
Operator
Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
Various remarks that management makes during this call about the company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of the company’s most recent quarterly report on Form 10-Q, which the company filed with the SEC this afternoon.
In addition, any forward-looking statements represent the company’s views only as of today and should not be relied upon as representing the company’s views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so even if its views change.
I would now like to turn the conference over to Jennifer Good, Trevi’s President and CEO. Please go ahead.
Jennifer Good
Good afternoon, and welcome to our first quarter 2022 earnings call and business update. Joining me today on this call are Lisa Delfini, Trevi’s Chief Financial Officer; and Dr. Bill Forbes, Trevi’s Chief Development Officer. Lisa and I have some prepared remarks then the three of us will be available for questions at the end.
2022 has already been an exciting year on the clinical front for Trevi, and there is more data to come. On this call, we will provide an update on the continued progress we are making on advancing the development of both of our programs.
However, before I do that, I want to quickly touch on the pipeline strategy at Trevi. We are focused on targeting the most debilitating aspects of disease where we also believe that there may be an opportunity to become disease-modifying over time. For instance, it is believed that for pruritus and PN, if you are able to break the itch scratch cycle for the patient by reducing or suppressing the itch and therefore the urge to scratch, then the skin and nodules will have time to heal. We have seen evidence supporting that in our clinical work to date.